Keybanc Initiates Coverage On NeuroPace with Overweight Rating, Announces Price Target of $18

Benzinga Newsdesk www.benzinga.com Neutral 50.7%

Neg 0% Neu 50.7% Pos 0%

Keybanc analyst Brett Fishbin initiates coverage on NeuroPace (NASDAQ:NPCE) with a Overweight rating and announces Price Target of $18.